Literature DB >> 31952808

Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties.

Ankush Garg1, Jagadish Prasad Hazra2, Malay Kumar Sannigrahi2, Sabyasachi Rakshit3, Sharmistha Sinha4.   

Abstract

Mutations in p53 protein, especially in the DNA-binding domain, is one of the major hallmarks of cancer. The R273 position is a DNA-contact position and has several oncogenic variants. Surprisingly, cancer patients carrying different mutant variants of R273 in p53 have different survival rates, indicating that the DNA-contact inhibition may not be the sole reason for reduced survival with R273 variants. Here, we probed the properties of three major oncogenic variants of the wild-type (WT) p53: [R273H]p53, [R273C]p53, and [R273L]p53. Using a series of biophysical, biochemical, and theoretical simulation studies, we observe that these oncogenic variants of the p53 not only suffer a loss in DNA binding, but they also show distinct structural stability, aggregation, and toxicity profiles. The WTp53 and the [R273H]p53 show the least destabilization and aggregation propensity. [R273C]p53 aggregation is disulfide mediated, leading to cross-β, thioflavin-T-positive aggregates, whereas hydrophobic interactions dominate self-assembly in [R273L]p53, leading to a mixture of amyloid and amorphous aggregates. Molecular dynamics simulations indicate different contact maps and secondary structures for the different variants along the course of the simulations. Our study indicates that each of the R273 variants has its own distinct property of stability and self-assembly, the molecular basis of which may lead to different types of cancer pathogenesis in vivo. These studies will aid the design of therapeutic strategies for cancer using residue-specific or process-specific protein aggregation as a target.
Copyright © 2019 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31952808      PMCID: PMC7002923          DOI: 10.1016/j.bpj.2019.12.015

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  52 in total

1.  Wetting of nonconserved residue-backbones: A feature indicative of aggregation associated regions of proteins.

Authors:  Mohan R Pradhan; Arumay Pal; Zhongqiao Hu; Srinivasaraghavan Kannan; Kwoh Chee Keong; David P Lane; Chandra S Verma
Journal:  Proteins       Date:  2016-01-07

2.  Modulation of binding of DNA to the C-terminal domain of p53 by acetylation.

Authors:  Assaf Friedler; Dmitry B Veprintsev; Stefan M V Freund; Karoly I von Glos; Alan R Fersht
Journal:  Structure       Date:  2005-04       Impact factor: 5.006

3.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

4.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

5.  Fibrillar aggregates of the tumor suppressor p53 core domain.

Authors:  Daniella Ishimaru; Leonardo R Andrade; Luciano S P Teixeira; Pablo A Quesado; Larissa M Maiolino; Priscila M Lopez; Yraima Cordeiro; Lilian T Costa; Wolfgang M Heckl; Gilberto Weissmüller; Debora Foguel; Jerson L Silva
Journal:  Biochemistry       Date:  2003-08-05       Impact factor: 3.162

Review 6.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

7.  TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Authors:  Pavla Brachova; Samuel R Mueting; Matthew J Carlson; Michael J Goodheart; Anna M Button; Sarah L Mott; Donghai Dai; Kristina W Thiel; Eric J Devor; Kimberly K Leslie
Journal:  Int J Oncol       Date:  2014-11-11       Impact factor: 5.650

8.  First-order rate-determining aggregation mechanism of p53 and its implications.

Authors:  GuoZhen Wang; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

Review 9.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

10.  Onset of disorder and protein aggregation due to oxidation-induced intermolecular disulfide bonds: case study of RRM2 domain from TDP-43.

Authors:  Sevastyan O Rabdano; Sergei A Izmailov; Dmitrii A Luzik; Adam Groves; Ivan S Podkorytov; Nikolai R Skrynnikov
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

View more
  5 in total

Review 1.  Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy.

Authors:  Emi Hibino; Hidekazu Hiroaki
Journal:  Biophys Rev       Date:  2022-01-11

2.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

Review 3.  An integrated view of p53 dynamics, function, and reactivation.

Authors:  Özlem Demir; Emilia P Barros; Tavina L Offutt; Mia Rosenfeld; Rommie E Amaro
Journal:  Curr Opin Struct Biol       Date:  2021-01-02       Impact factor: 6.809

4.  Comprehensive Analysis of the Carcinogenic Process, Tumor Microenvironment, and Drug Response in HPV-Positive Cancers.

Authors:  Xiaorong Yu; Jiankai Xu; Dahua Xu; Xiaoman Bi; Hong Wang; Yanda Lu; Meng Cao; Wenxiang Wang; Zhizhou Xu; Dehua Zheng; Liyang Chen; Xiaodian Zhang; Shaojiang Zheng; Kongning Li
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

5.  Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity.

Authors:  Emi Hibino; Takeshi Tenno; Hidekazu Hiroaki
Journal:  Front Mol Biosci       Date:  2022-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.